Is ABIO a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

338 people get ABIO articles and Market Currents by email alert.

Get email alerts on ABIO »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

Arca Biopharma Rallies On New Plans For A Phase III Trial
Brian L. Wilson • Mon, Feb 4 • 2 Comments
Arca Biopharma: Heart Disease Drug Looks Promising
Michael Catalin Vlaicu • Tue, May 12, 2009 • 1 Comment

To learn more about Seeking Alpha Pro, click here.

A Turnaround Stock Investors Should Love
BuySellShort • Thu, Mar 14 • 5 Comments
Will the Next Apple or Google Be Found Among These Micro Caps?
Kurtis Hemmerling • Thu, Aug 18, 2011 • 9 Comments
Competitive Technologies: Short Squeeze Coming or Another Leg Down?
David Greene • Wed, Aug 25, 2010 • 29 Comments
Drug Pipeline Pulse Check: A Challenging Week
Research Recap • Tue, Mar 30, 2010
BioMed News Bytes: Transcept, ProUroCare, SciClone, ABIO
Mike Havrilla • Tue, Nov 24, 2009
MercadoLibre: Bullish Options Strategy
Option Maestro • Tue, Nov 24, 2009
13 Extreme FDA Trades
Mike Havrilla • Tue, Jun 2, 2009 • 12 Comments
Einhorn's Greenlight Capital's Big Bets on Gold: 13F Filing - Q1
Market Folly • Sun, May 31, 2009 • 5 Comments
Pending FDA Decisions: 12 Extreme Trades
Mike Havrilla • Wed, May 20, 2009 • 2 Comments
Vanda Pharma: An Extreme FDA Trade That Paid; 9 More to Go
Mike Havrilla • Thu, May 7, 2009 • 9 Comments
Trading FDA Decisions: 14 Candidates
Mike Havrilla • Thu, Mar 12, 2009 • 3 Comments
Updated Clinical Trial and FDA Calendars
Mike Havrilla • Thu, Jan 29, 2009 • 1 Comment

There are no Transcripts on ABIO.

Gencaro™ Potential Efficacy in Preventing Atrial Fibrillation Paper Published in JACC: Heart Failure

Business Wire (Jun 6, 2013)
ARCA biopharma Announces Closing of $20 Million Equity Offering

Business Wire (Jun 5, 2013)
ARCA biopharma Announces Pricing of $20 Million Equity Offering

Business Wire (May 30, 2013)
ARCA Announces Death of Board Member Burton E. Sobel, Preeminent Physician Scientist and Academic Leader

Business Wire (May 6, 2013)
ARCA biopharma and Medtronic to Collaborate on Atrial Fibrillation Clinical Trial for GencaroTM

Business Wire (Apr 22, 2013)
CEO of ARCA biopharma to Speak on Changing Paradigms in Drug Development at ACC.13 Conference on March 10, 2013

Business Wire (Mar 8, 2013)
ARCA biopharma, Inc. Announces Reverse Stock Split

Business Wire (Mar 5, 2013)
Unmet Medical Need in Treatment of Heart Failure Patients with Atrial Fibrillation Highlighted in Articles in Inaugural Issue of JACC: Heart Failure

Business Wire (Feb 6, 2013)
New Adaptive Phase 3 Trial Planned for GencaroTM in Atrial Fibrillation

Business Wire (Jan 29, 2013)
GencaroTM Effect on Reducing Ventricular Arrhythmias Paper Published in Circulation: Arrhythmia and Electrophysiology

Business Wire (Jan 3, 2013)
CORRECTING AND REPLACING GencaroTM Cardiovascular Effect on Patients with Atrial Fibrillation Paper Published in European Journal of Heart Failure

Business Wire (Dec 12, 2012)
GencaroTM Pharmacogenetic Effect Paper Published in Peer Reviewed Journal PLOS ONE

Business Wire (Oct 10, 2012)
GencaroTM's Norepinephrine Lowering Likely Contributes to Its Effect in Atrial Fibrillation Prevention

Business Wire (Mar 26, 2012)
ARCA biopharma Announces Additional Patent Issued for Methods for Treatment with Bucindolol Based on Genotype of Patient

Business Wire (Jan 19, 2012)
ARCA biopharma Announces Additional Patent Issued for Methods for Treatment with Bucindolol Based on Genetic Targeting

Business Wire (Dec 30, 2011)
ARCA biopharma Announces Private Placement of $1.75 Million with Institutional Investors

Business Wire (Dec 22, 2011)
Market Extra: After-hours trades still risky, a decade later

at MarketWatch.com (Jun 9, 2011)
Movers & Shakers: Monday's biggest gaining and declining stocks

at MarketWatch.com (May 17, 2010)

ABIO vs. ETF Alternatives

Company Description

ARCA is a biopharmaceutical company whose principal focus is developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA’s lead product candidate is GencaroTM (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator being... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 30, 12:44 PM Midday top 10 gainers: NBG +475%. CLWR +24%. NVE +22%. GV +19%. AIQ +17%. BVX +16%. CLSN +16%. AAU +15%. BAA +14%. GURE +13%.
Midday top 10 Losers: ABIO -30%. VIMC -20%. DLIA -13%. VRTB -11%. CVI -11%. HSOL -10%. WPCS -10%. AGII -9%. ARTX -8%. ALVR -8%. 5 Comments [On the Move]
Thursday, May 30, 9:29 AM Arca Biopharma (ABIO) plunges 30% premarket after announcing the pricing of a $20M equity offering. The company will issue ~125K preferred shares ($160/share, convertible to 100 shares of common, come with a warrant to purchase 50 shares of common at $1.60/share, immediately exercisable) with related warrants to buy a total of 6.25M common shares. (PR) Comment! [On the Move, Healthcare]
Thursday, May 30, 9:13 AM Premarket gainers: NVE +22%. CLWR +20%. MY +15%. CLSN +13%. HSOL +12%. CPST +10%. EXPR +9%. LXRX +8%. BLDP +8%. VRNG +7%. RSOL +6%. WFR +6%. AMRN +6%. FSLR +6%. ALU +6%. EMC +6%. STP +5%. HIMX +5%. OCZ +5%.
Losers: ABIO -31%. BIG -9%. VNR -5%. BPFH -5%. 1 Comment [On the Move]
Tuesday, April 23, 12:56 PM Midday top 10 gainers: SCON +118%. MEMS +49%. CZR +29%. NFLX +24%. ARL +18%. CPLA +18%. VECO +17%. HSTM +17%. SANM +16%. ILMN +15%.
Midday top 10 losers: CPRX -15%. IIVI -13%. UNTK -13%. ABIO -13%. CASM -10%. EFUT -9%. GASS -9%. TAX -8%. SIFY -7%. USTR -7%. Comment! [On the Move]
Monday, April 22, 9:10 AM Premarket gainers: PWER +56%. ABIO +47%. MPR +40%. SILC +7%. SAND +5%. Comment! [On the Move]
Monday, April 22, 8:43 AM Arca Biopharma (ABIO) soars 35% premarket. The company says it will collaborate with Medtronic (MDT) on a Phase 2b clinical trial for Gencaro, ABIO's lead developmental drug for the treatment of cardiac rhythm disorders. Comment! [Healthcare, On the Move]
Tuesday, March 26, 12:12 PM Arca Biopharma (ABIO -6.2%) trades down today after the company filed a registration with the SEC to sell, from time to time, up to $20M of its stock and warrants. Comment! [Healthcare, On the Move]
Friday, March 8, 12:44 PM Midday top 10 gainers: AQ +36%. GMXR +35%. MEET +22%. AMBA +22%. III +22%. ABIO +21%. PRGN +20%. BVSN +19%. P +18%. WG +17%.
Midday top 10 losers: SKUL -22%. PGRX -19%. SUTR -16%. TECUA -16%. FREE -15%. ANGO -13%. MXWL -13%. AVG -11%. ARCI -10%. OTIV -8%. Comment! [On the Move]
Tuesday, March 5, 10:50 AM ARCA Biopharma (ABIO +6.7%) trades up after announcing a 6-for-1 reverse split of its common stock, which became effective after the close yesterday, and trading on the NASDAQ on a split adjusted basis as of today. The reverse split reduces ABIO's number of shares issued and outstanding from approximately 19.1M shares to approximately 3.2M shares. Comment! [Healthcare, On the Move]
Wednesday, January 30, 9:29 AM ARCA Biopharma (ABIO) +51.9% premarket after announcing plans for a phase 3 adaptive design clinical trial for its lead developmental drug, Gencaro, in atrial fibrillation. Medtronic (MDT) will be collaborating on the initial, phase 2B portion of the proposed trial. Comment! [Healthcare, On the Move]
Wednesday, December 12, 2012, 1:50 PM Arca Biopharma (ABIO +30%) soars today after announcing that a paper was published in the European Journal of Heart Failure which presented data demonstrating that patients with established atrial fibrillation who received ABIO's Gencaro had improvements in heart failure clinical endpoints. The data also showed that Gencaro made it more likely for patients to achieve ventricular rate control, and that Gencaro improved cardiovascular clinical endpoints for those patients who did achieve rate control. Comment! [Healthcare, On the Move, Global & FX]
Friday, March 26, 2010, 3:27 PM ARCA Biopharma (ABIO +236.6%) shares skyrocket after the company receives a patent protecting its heart-failure treatment methods. (PR) Comment!

Brian L. Wilson
$ABIO looks like it's going to have an equity financing soon, I'd be careful about chasing it too soon http://bit.ly/11HHKcF
Feb 4, 5:27 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LEIGHDIST
finally seeing green on my protfolio, $ABIO,$AUY,$CLSN what a great day..... congrats to $ISIS
Jan 30, 10:41 AM
Reply (5)

• !Report Abuse
View all 5 replies
LEIGHDIST: got hit enough with amrn i don't take a chance anymore anytime i see green i take big or small, i think i will do like you get out on abio
Jan 31, 11:24 AM
• !Report Abuse
LEIGHDIST: Joe ended up selling my portion of abio also at .73 took a gain also but i will go back as soon as it drops hopefully under .50
Feb 5, 3:28 PM
• !Report Abuse
Add a reply...

140 characters

LEIGHDIST
$ABIO, yeah great start to the day
Jan 30, 9:42 AM
Reply (4)

• !Report Abuse
View all 4 replies
joe kelly: There are some naysayers on Stocktwits. Don't know why. More success to you Leigh.
Jan 30, 10:28 AM
• !Report Abuse
LEIGHDIST: you to Joe, it will be a long progress but holding on, for one day the fda approval or to complete the phase 3
Jan 30, 10:34 AM
• !Report Abuse
Add a reply...

140 characters

LEIGHDIST
$ABIO looking good for long term, moving nicely today again
12/12/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

LEIGHDIST
finally seeing green on my protfolio, $ABIO,$AUY,$CLSN what a great day..... congrats to $ISIS
Jan 30, 10:41 AM
Reply (5)

• !Report Abuse
View all 5 replies
LEIGHDIST: got hit enough with amrn i don't take a chance anymore anytime i see green i take big or small, i think i will do like you get out on abio
Jan 31, 11:24 AM
• !Report Abuse
LEIGHDIST: Joe ended up selling my portion of abio also at .73 took a gain also but i will go back as soon as it drops hopefully under .50
Feb 5, 3:28 PM
• !Report Abuse
Add a reply...

140 characters

LEIGHDIST
$ABIO, yeah great start to the day
Jan 30, 9:42 AM
Reply (4)

• !Report Abuse
View all 4 replies
joe kelly: There are some naysayers on Stocktwits. Don't know why. More success to you Leigh.
Jan 30, 10:28 AM
• !Report Abuse
LEIGHDIST: you to Joe, it will be a long progress but holding on, for one day the fda approval or to complete the phase 3
Jan 30, 10:34 AM
• !Report Abuse
Add a reply...

140 characters

ABIO Arca Biopharma, Inc.

ABIO

Arca Biopharma, Inc.